Navigation Links
New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline

SCOTTSDALE, Ariz., June 12 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area (

MedPredict interviewed renowned Alzheimer's disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference.

"In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to Jeff Berk, MedPredict's president and lead author of this report. "The panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer's disease and treatment at the earliest stages of dementia."

"The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and drugs like Dimebon, specifically designed to enhance mental function," says Berk. "They also update the progress coming out of ADNI, the Alzheimer's Disease Neuroimaging Initiative, and describe how some amazing diagnostic tools have now been incorporated into the pivotal trials of these exciting therapeutics."

Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca/Targacept, Avid, Baxter, Bayer-Schering/Avid Radiopharmaceuticals, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Elan/Transition Therapeutics/AZ, Elan/Wyeth, Envivo, Eisai, Forest/Merz/Lundbeck/Daiichi-Sankyo, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Link, Myriad, Novartis, Oligomerix, Pfizer, Pfizer/Medivation, Prana, Roche/Memory, Satori, TauRx, TauTaTis, Transtech, and Wyeth.

The full report may be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
3. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
4. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
5. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
6. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
7. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
8. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
9. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
10. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
11. BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After Youve Eaten Asparagus?
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, ... and rodent control solutions , Bird Free, ... works across all sensory modalities including visual, smell, taste and touch, enabling safe, effective ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/25/2015)... November 25, 2015 2 nouvelles études ... les différences entre les souches bactériennes retrouvées dans ... des êtres humains . Ces recherches  ouvrent une ... la prise en charge efficace de l,un des ... les chats .    --> 2 nouvelles ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):